Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

ACT Genomics and LSI Medience Forge Strategic Partnership to Advance in the Japanese Market

NextEdge Admin

01 Jul 2024

2 min 22 sec

personalized medicine,bioinformatics,Oncology

ACT Genomics Co. Ltd. (ACTG) and LSI Medience Corporation (LSIM) have entered into a Memorandum of Understanding (MOU) to collaborate in the Japanese healthcare market, marking a significant stride towards advancing personalized medicine in the region.

ACTG, headquartered in Neihu District, Taipei City, Taiwan, is a renowned leader in comprehensive cancer genomic profiling. Their expertise lies in genomic profiling technologies, providing tailored solutions for cancer treatment guidelines, risk assessment, and immunotherapy evaluation globally. LSIM, a Tokyo-based subsidiary of PHC Holdings Corporation, brings robust capabilities in clinical testing and services, established over decades of operation in Japan.

The collaboration aims to integrate ACTG's cutting-edge genomic testing solutions with LSIM's strong analytical capabilities in clinical diagnostics. Initially, they will focus on enhancing genomic profiling in clinical research settings, offering personalized insights to Japanese researchers and healthcare institutions. This partnership is expected to drive advancements in precision medicine, contributing to improved patient outcomes across various cancers and medical scenarios.

Walt Ling, CEO of ACTG, expressed optimism about the partnership's potential to redefine standards in precision medicine, emphasizing their commitment to innovation and personalized healthcare solutions. Kenichi Uchino, President of LSIM, echoed this sentiment, highlighting their joint effort to accelerate technological innovation and contribute positively to Japan's healthcare sector.

Further details regarding specific projects and initiatives resulting from this collaboration will be disclosed as they are developed, underscoring their shared dedication to advancing healthcare through genomic innovation and personalized medicine in Japan.